AllianceBernstein’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

AllianceBernstein’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,931	Closed	-$208K	–	3495
2021 Q1	$208K	Hold	7,931	–	–	﹤0.01%	3052
2020 Q4	$287K	Sell	7,931 -2,332	-23%	-$84.3K	﹤0.01%	2879
2020 Q3	$363K	Sell	10,263 -221	-2%	-$9.61K	﹤0.01%	2709
2020 Q2	$445K	Buy	+10,484	New	+$707K	﹤0.01%	2687

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

AllianceBernstein's EVFM Position: Q2 2021 in Review

AllianceBernstein sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 7,931 shares — an estimated $208K sold.

AllianceBernstein first reported a position in EVFM in Q2 2020 and held it in 4 quarters. The position peaked at $445K in Q2 2020. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

AllianceBernstein reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
AllianceBernstein sold 7,931 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $208K.
AllianceBernstein first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
AllianceBernstein's Evofem Biosciences, Inc. Common Stock position peaked at $445K in Q2 2020.
81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.